Cargando…
Endogenous glutamine decrease is associated with pancreatic cancer progression
Pancreatic ductal adenocarcinoma (PDAC) is becoming the second leading cause of cancer-related death in the Western world. The mortality is very high, which emphasizes the need to identify biomarkers for early detection. As glutamine metabolism alteration is a feature of PDAC, its in vivo evaluation...
Autores principales: | Roux, Cecilia, Riganti, Chiara, Borgogno, Sammy Ferri, Curto, Roberta, Curcio, Claudia, Catanzaro, Valeria, Digilio, Giuseppe, Padovan, Sergio, Puccinelli, Maria Paola, Isabello, Monica, Aime, Silvio, Cappello, Paola, Novelli, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707027/ https://www.ncbi.nlm.nih.gov/pubmed/29221133 http://dx.doi.org/10.18632/oncotarget.20545 |
Ejemplares similares
-
Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest
por: Capello, Michela, et al.
Publicado: (2015) -
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis
por: Principe, Moitza, et al.
Publicado: (2017) -
IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine
por: Roux, Cecilia, et al.
Publicado: (2021) -
Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners
por: Cappello, Paola, et al.
Publicado: (2018) -
Endogenous glutamine production in critically ill patients: the effect of exogenous glutamine supplementation
por: Mori, Maiko, et al.
Publicado: (2014)